Shanghai

Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC

Retrieved on: 
Friday, December 10, 2021
Ligand, FDA, Infection, Lung cancer, Junshi, Esophageal cancer, Cancer, Risk, HIV disease progression rates, Breast, NDA, Review, Food, National Medical Products Administration, PD-L1, World, Esophagus, United, NPC, Stomach, Lung, SSE, Pharynx, NSCLC, GLOBE, Safety, Mortality, Microbiology, IDMC, EUA, Blas, PD-1, New Drug Application, PFS, Shanda, NMPA, Eli Lilly, WCLC, Medicine, Patient, Peking Union Medical College, Kidney, US Foods, R & D, Fast Track, Bamlanivimab, Cisplatin, Breakthrough therapy, PD-L2, Bamlanivimab/etesevimab, Marketing, Mucosal melanoma, Severe acute respiratory syndrome coronavirus 2, Liver, Therapy, World Health Organization, Progression-free survival, Conference, BLA, OS, ALK, HKEX, Skin, Autoimmunity, Pharmaceutical industry

The study enrolled 465 NSCLC patients in 63 centers in China, among which 220 were squamous NSCLC patients and 245 were non-squamous NSCLC patients.

Key Points: 
  • The study enrolled 465 NSCLC patients in 63 centers in China, among which 220 were squamous NSCLC patients and 245 were non-squamous NSCLC patients.
  • Existing domestic and overseas studies have shown that monotherapy or combination chemotherapy of anti-PD-(L)1 monoclonal antibody has already become new standard for the first-line treatment of NSCLC.
  • Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple other cancer types.
  • Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

TPFG Environment Investment Limited Announces Disposition of Shares of Biorem Inc.

Retrieved on: 
Tuesday, December 7, 2021
SEDAR, Share (finance), Report, National instrument, News, Security (finance)

Shanghai, China--(Newsfile Corp. - December 7, 2021) - In accordance with regulatory requirements, TPFG Environment Investment Limited announces that it has disposed of 23,434,121 common shares ("Shares") of Biorem Inc. (the "Issuer"), a clean technology company listed on the TSXV to the Issuer.

Key Points: 
  • Shanghai, China--(Newsfile Corp. - December 7, 2021) - In accordance with regulatory requirements, TPFG Environment Investment Limited announces that it has disposed of 23,434,121 common shares ("Shares") of Biorem Inc. (the "Issuer"), a clean technology company listed on the TSXV to the Issuer.
  • Immediately prior to the disposition of securities described in this news release, TPFG owned or controlled 23,434,121 Shares representing an approximate 60.6% interest in the Issuer.
  • Immediately following the transaction that triggered the requirement to file this news release, TPFG no longer owns any shares in the Issuer.
  • TPFG disposed of the Shares of the Issuer for the purposes of liquidating its entire position in the Issuer in one transaction.

DayDayCook Launches Food Tech Accelerator Program

Retrieved on: 
Tuesday, December 7, 2021
City, Carbon, Glycemic index, GLOBE, Good Food, Technology, Alchemy, RTC, Â, Food Tech, Food, Salad, CEO, Nature, Diabetes, Meal, RTH, GFM, KPMG, Time, Program, DDC, Pharmacy, Conditional sentence, Solution, Nutrient, Social media, Document, Sale, Mentorship, Interest, Risk management, Fast food, Aquaculture

HONG KONG, Dec. 07, 2021 (GLOBE NEWSWIRE) -- DayDayCook (DDC), a leading content driven direct-to-consumer brand in China, today announces the launch of Hong Kongs first food tech accelerator program, The Good Food Accelerator Program, with the goal of building a world-class food tech ecosystem in Hong Kong.

Key Points: 
  • HONG KONG, Dec. 07, 2021 (GLOBE NEWSWIRE) -- DayDayCook (DDC), a leading content driven direct-to-consumer brand in China, today announces the launch of Hong Kongs first food tech accelerator program, The Good Food Accelerator Program, with the goal of building a world-class food tech ecosystem in Hong Kong.
  • The Good Food Accelerator Programs mission is to build a leading food tech ecosystem in Hong Kong, and kickstart a stream of commercially-viable products and innovative solutions, said Norma Chu, CEO of DayDayCook.
  • 70/30 Food Science & Tech A Shanghai-based food delivery venture providing wholesome plant-based takeaway food that is both flavorful and affordable.
  • The Good Food Accelerator Program is powered by the Good Food Movement (GFM), a program fully supported by DayDayCook and endorsed by Cyberport.

ECMOHO Limited Announces the Appointment of independent director of the Board

Retrieved on: 
Monday, December 6, 2021
News, Direction générale de l'armement, Technology, Private Securities Litigation Reform Act, Company, BNP Paribas, Health, Audit committee, MBA, Solution, Longevity, Securities Exchange Act of 1934, COVID-19, U.S. Securities and Exchange Commission, Investment, GLOBE, Tsinghua University, Marketing, Terminology, Board, Efficiency, Ecosystem, Sustainability Accounting Standards Board, Growth, Audit, Security (finance)

Mr. Greg Ye tendered to the Board his resignation as an independent director of the Board, the chair and a member of the audit committee of the Board and a member of the Nominating and Corporate Governance Committee of the Board for personal reasons, effective from December 1, 2021.

Key Points: 
  • Mr. Greg Ye tendered to the Board his resignation as an independent director of the Board, the chair and a member of the audit committee of the Board and a member of the Nominating and Corporate Governance Committee of the Board for personal reasons, effective from December 1, 2021.
  • The Board appointed Mr. Yuan Fang as an independent director of the Board, the chair and a member of the Audit Committee of the Board and a member of the Nominating and Corporate Governance Committee of the Board, effective from December 1, 2021.
  • Upon the effectiveness of Mr. Greg Yes resignation and the appointment of Mr. Yuan Fang, the Board consisted of five directors, including two independent directors.
  • Mr. Yuan Fang is well qualified to serve as an independent director of the Board and possesses substantial experience in venture capital investment, operation management and investment banking.

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

Retrieved on: 
Sunday, December 5, 2021
Patient, Infant, Safety, Eli Lilly, HKEX, The New England Journal of Medicine, Hospital, Macau, R & D, Severe acute respiratory syndrome coronavirus 2, SSE, Autoimmunity, Immunoglobulin G, Eli Lilly and Company, Ageing, Post-exposure prophylaxis, Therapy, COVID-19, Vaccination, Bamlanivimab, Institute, Death, GLOBE, Marketing, HIV disease progression rates, FDA, ACE2, Infection, Bamlanivimab/etesevimab, EUA, Waksman Institute of Microbiology, Chinese Academy of Sciences, NMPA, Statistics, Pharmaceutical industry, Vaccine

The Therapy has been the first and only authorized neutralizing antibody therapy for emergency use in COVID-19 individuals under the age of 12 and offers treatment and prevention options to high-risk individuals of any age.

Key Points: 
  • The Therapy has been the first and only authorized neutralizing antibody therapy for emergency use in COVID-19 individuals under the age of 12 and offers treatment and prevention options to high-risk individuals of any age.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.
  • JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in 15 countries and regions worldwide.
  • Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China’s National Reimbursement Drug List

Retrieved on: 
Friday, December 3, 2021
Patient, Lung, Skin, Review, Safety, PD-L1, Eli Lilly, PD-L2, HKEX, Esophagus, Esophageal cancer, R & D, Severe acute respiratory syndrome coronavirus 2, Kidney, SSE, Breast, Autoimmunity, BLA, Microbiology, Ligand, Therapy, Bamlanivimab, Nasopharyngeal carcinoma, Melanoma, Cisplatin, Mucosal melanoma, Pharynx, Insurance, Stomach, GLOBE, Blas, Marketing, NDA, Fast Track, FDA, NPC, Category, United, PD-1, Infection, NRDL, Bamlanivimab/etesevimab, EUA, NMPA, Breakthrough therapy, Liver, Pharmaceutical industry

Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma and nasopharyngeal carcinoma.

Key Points: 
  • Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma and nasopharyngeal carcinoma.
  • InDecember 2020, toripalimab was successfully included in the updated National Reimbursement Drug List for the indication of the second-line treatment of unresectable or metastatic melanoma.
  • Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple other cancer types.
  • Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer

Retrieved on: 
Friday, December 3, 2021
Private Securities Litigation Reform Act, Patient, Ovarian cancer, Coronavirus, Safety, PARP, Niraparib, Risk, Disease, Forward-looking statement, Company, NORA, Woman, Health, Clinical trial, Progression-free survival, SAN, COVID-19, PFS, GSK, U.S. Securities and Exchange Commission, Death, Degenerative disease, Endometrial cancer, GLOBE, Adult, Cholangiocarcinoma, Infection, NRDL, Maintenance, ADP, Zai, NASDAQ, Peritonitis, Pharmaceutical industry, Medical imaging, Birth control, Online shopping

The inclusion of ZEJULA in the NRDL for first-line maintenance treatment of ovarian cancer is an important step in achieving that mission.

Key Points: 
  • The inclusion of ZEJULA in the NRDL for first-line maintenance treatment of ovarian cancer is an important step in achieving that mission.
  • We are grateful for this action by the NHSA to make ZEJULA more accessible to Chinese patients with ovarian cancer.
  • In December 2020, ZEJULA was included in the NRDL as a maintenance treatment of adult patients with platinum-sensitive, recurrent ovarian cancer.
  • New agents that prolong the duration of response following platinum-based treatment and delay the relapse of ovarian cancer will benefit patients with ovarian cancer inChina.

Qutoutiao Inc. Announces Plan to Implement ADS Ratio Change

Retrieved on: 
Thursday, December 2, 2021
Sale, ADSS, Bank, ADS, American depositary receipt, Industry, Private Securities Litigation Reform Act, Forward-looking statement, Company, SEC, BNY Mellon, Tax, GLOBE, Advertising, Terminology, Nasdaq, NASDAQ, Security (finance), Public relations

The Company anticipates that the change in the ADS Ratio will be effective on or about December 10, 2021.

Key Points: 
  • The Company anticipates that the change in the ADS Ratio will be effective on or about December 10, 2021.
  • For Qutoutiaos ADS holders, the change in the ADS Ratio will have the same effect as a one-for-ten reverse ADS split.
  • The change in the ADS Ratio will have no impact on Qutoutiaos underlying Class A ordinary shares, and no Class A ordinary shares will be issued or cancelled in connection with the change in the ADS Ratio.
  • As a result of the change in the ADS Ratio, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the change in the ADS Ratio will be equal to or greater than ten times the ADS trading price before the change.

NIO Inc. Provides November 2021 Delivery Update

Retrieved on: 
Wednesday, December 1, 2021
NIO, Motor vehicle, SUV, NIO ES8, ES6, Private Securities Litigation Reform Act, Forward-looking statement, NYSE, SEC, EC6, Solution, 2600-series (CTA), Annual report, Adaa Khan, ES8, GLOBE, Terminology, Battery, NIO EC6, Privacy, NIO ES6, Mobile backend as a service, Animal, Risk management

NIO delivered 10,878 vehicles in November 2021, increasing by 105.6% year-over-year

Key Points: 
  • NIO delivered 10,878 vehicles in November 2021, increasing by 105.6% year-over-year
    NIO delivered 80,940 vehicles year-to-date in 2021 in total, increasing by 120.4% year-over-year
    Cumulative deliveries of the ES8, ES6 and EC6 as of November 30, 2021 reached 156,581
    SHANGHAI, China, Dec. 01, 2021 (GLOBE NEWSWIRE) -- NIO Inc. (NIO or the Company) (NYSE: NIO), a pioneer and a leading company in the premium smart electric vehicle market, today announced its November 2021 delivery results.
  • NIO delivered 10,878 vehicles in November 2021, representing a solid 105.6% year-over-year growth.
  • NIO has delivered 80,940 vehicles year-to-date in 2021 in total, representing a strong increase of 120.4% year-over-year.
  • As of November 30, 2021, cumulative deliveries of the ES8, ES6 and EC6 reached 156,581 vehicles.

WWP Beauty Opened New APAC Design Innovation Hub Shanghai

Retrieved on: 
Wednesday, December 1, 2021
Innovation Hub, Beauty, GLOBE, Industry, Solution, WWP

On November 12th, 2021, the company opened their newest Design Innovation Hub location in Shanghai, China.

Key Points: 
  • On November 12th, 2021, the company opened their newest Design Innovation Hub location in Shanghai, China.
  • The WWP Beauty Design Innovation Hub Shanghai office is made from a recycled ocean container, reducing construction waste and aligning with the company mission of building a more clean, inclusive and sustainable future.
  • WWP Beauty Design Innovation Hub Shanghai will deliver integrated sourcing services and the newest design solutions, within its local market and around the globe.
  • Based on this new office space, WWP Beauty gives customers full-service solutions for beauty products in Shanghai.